Changes in Beneficial Ownership · 4
Monopar Therapeutics
MNPRNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
rdgdoc.xml
Filing details
- Report period
- 2026-10-01
- Issuer
- Monopar Therapeutics
- Issuer CIK
- 0001645469
- Trading symbol
- MNPR
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- STARR CHRISTOPHER M
- Reporting owner CIK
- 0001235470
- Relationship
- Director
- Address
- 1000 SKOKIE BLVD SUITE 350, WILMETTE, IL, 60091
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-01 | M · Form 4[F1] | 8,400 | A | 0.005 | 13,573 | D |
| Common Stock | 2026-10-01 | S · Form 4[F1] | 4,631 | D | 78.09[F4] | 8,942 | D |
| Common Stock | 2026-10-01 | S · Form 4[F1] | 2,970 | D | 78.82[F5] | 5,972 | D |
| Common Stock | 2026-10-01 | S · Form 4[F1] | 799 | D | 79.67[F6] | 5,173 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 9,880 | I | See Footnote[F3] |
Table key
- I
- Indirect
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option | 0.005 | 2026-10-01 | M · Form 4[F1] | 8,400 | D | 0 | [F2] | 2027-02-19 | Common Stock | 8,400 | 8,400 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 28, 2026.↩ 1↩ 2↩ 3↩ 4↩ 5
- F2
- On February 20, 2017, the reporting person was granted stock options to purchase up to 16,800 shares of common stock. Stock options vest 6/48ths on the six-month anniversary of grant date and 1/48th per month thereafter.↩ 1
- F3
- Represents shares of common stock held by the Christopher M. Starr and Sheri L. Starr Revocable Trust over which Dr. Starr serves as Trustee.↩ 1
- F4
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.50 to $78.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.↩ 1
- F5
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.50 to $79.49, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.↩ 1
- F6
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.50 to $80.01, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4.↩ 1
Signature 1
- Signed
- /s/ Quan Vu, Attorney-in-fact
- Date
- 2026-10-05